Edition:
United Kingdom

Pulmatrix Inc (PULM.OQ)

PULM.OQ on NASDAQ Stock Exchange Capital Market

0.89USD
23 Aug 2019
Change (% chg)

$-0.03 (-3.16%)
Prev Close
$0.92
Open
$0.94
Day's High
$1.02
Day's Low
$0.89
Volume
342,681
Avg. Vol
73,742
52-wk High
$4.62
52-wk Low
$0.72

Latest Key Developments (Source: Significant Developments)

Pulmatrix Reports Q2 2019 Results
Monday, 5 Aug 2019 

Aug 5 (Reuters) - Pulmatrix Inc ::PULMATRIX REPORTS Q2 2019 RESULTS.Q2 REVENUE $4.8 MILLION.QUARTERLY LOSS PER SHARE $0.41.AS OF JUNE 30, 2019, PULMATRIX HAD $31.8 MILLION IN CASH.RECORDED A CHARGE OF $6.5 MILLION FOR IMPAIRMENT OF GOODWILL IN Q2 OF 2019.  Full Article

Pulmatrix Says Received Non-Compliance Letter From Nasdaq
Monday, 22 Jul 2019 

July 22 (Reuters) - Pulmatrix Inc ::PULMATRIX INC - RECEIVED NON-COMPLIANCE LETTER FROM NASDAQ.  Full Article

Empery Asset Management Lp Reports 9.99 Pct Passive Stake In Pulmatrix
Monday, 15 Apr 2019 

April 15 (Reuters) - Pulmatrix Inc ::EMPERY ASSET MANAGEMENT LP REPORTS 9.99 PERCENT PASSIVE STAKE IN PULMATRIX INC AS OF APRIL 3 - SEC FILING.  Full Article

Pulmatrix Enters Into Binding Term Sheet with Cipla Technologies LLC
Monday, 1 Apr 2019 

April 1 (Reuters) - Cipla Ltd ::PULMATRIX ENTERS INTO BINDING TERM SHEET WITH CIPLA TECHNOLOGIES LLC FOR THE DEVELOPMENT AND COMMERCIALIZATION OF PULMAZOLE.PULMATRIX - BINDING TERM SHEET EXECUTED ON APRIL 1, 2019 LAYS GROUNDWORK FOR ENTRY INTO A DEFINITIVE AGREEMENT DURING 2ND QUARTER OF 2019.PULMATRIX - CIP TEC TO MAKE AN UPFRONT PAYMENT OF $22 MILLION TO CO IN EXCHANGE FOR ASSIGNMENT OF ALL RIGHTS TO PULMAZOLE TO CIP TEC.PULMATRIX - ENTRY INTO DEFINITIVE AGREEMENT IS CONTINGENT UPON, CO HAVING AT LEAST $15 MILLION IN UNENCUMBERED FUNDS.PULMATRIX INC - PULMATRIX TO RETAIN RIGHT TO RECEIVE 50% OF FREE CASH FLOW FROM FUTURE SALES OF PULMAZOLE.PULMATRIX INC - CO TO REMAIN PRIMARILY RESPONSIBLE FOR IMPLEMENTATION OF CLINICAL DEVELOPMENT OF PULMAZOLE.PULMATRIX INC - CIP TEC WILL BE RESPONSIBLE FOR IMPLEMENTATION OF COMMERCIALIZATION OF PULMAZOLE.  Full Article

Pulmatrix, Inc. Announces 1-For-10 Reverse Stock Split
Tuesday, 5 Feb 2019 

Pulmatrix Inc ::PULMATRIX, INC. ANNOUNCES 1-FOR-10 REVERSE STOCK SPLIT.PULMATRIX, INC. ANNOUNCES 1-FOR-10 REVERSE STOCK SPLIT.PULMATRIX INC - REVERSE SPLIT OF COMMON STOCK IS EFFECTIVE AS OF 5:00 PM EASTERN TIME, FEBRUARY 5, 2019.  Full Article

Pulmatrix Announces Pricing Of Public Offering Of Common Stock
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - Pulmatrix Inc ::PULMATRIX, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 5.32 MILLION COMMON SHARES PRICED AT $0.17PER SHARE.  Full Article

Pulmatrix Inc Announces Proposed Public Offering Of Common Stock
Wednesday, 30 Jan 2019 

Jan 30 (Reuters) - Pulmatrix Inc ::PULMATRIX, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.PULMATRIX INC - INTENDS TO USE NET PROCEEDS FROM OFFERING FOR WORKING CAPITAL AND GENERAL CORPORATE PURPOSES.  Full Article

Pulmatrix Inc Announces Pricing Of Public Offering Of Common Stock
Tuesday, 29 Jan 2019 

Jan 28 (Reuters) - :PULMATRIX, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 1.56 MILLION COMMON SHARES PRICED AT $0.17PER SHARE.  Full Article

Pulmatrix Inc. Announces Proposed Public Offering Of Common Stock
Monday, 28 Jan 2019 

Jan 28 (Reuters) - Pulmatrix Inc ::PULMATRIX, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.  Full Article

Pulmatrix Inc - QTRLY Loss Per Share $0.13
Friday, 3 Aug 2018 

Pulmatrix Inc ::PULMATRIX REPORTS Q2 2018 RESULTS.PULMATRIX INC - QTRLY LOSS PER SHARE $0.13.PULMATRIX INC - AS OF JUNE 30, 2018, PULMATRIX HAD $8.3 MILLION IN CASH AND CASH EQUIVALENTS.PULMATRIX INC QTRLY LOSS PER SHARE $0.13.  Full Article